iCo Therapeutics is a re-profiling company engaged in re-dosing or reformulating drugs with clinical history for new or expanded indications. The company owns the global rights to three products: iCo-007, currently in a Phase I trial in diabetic macular edema patients; iCo-008, a human monoclonal antibody against eotaxin-1 with Phase II clinical history; and iCo-009, an oral reformulation of a generic antifungal and anti-parasitic intravenous drug that, to date, has shown positive preclinical results. For more information, visit the company’s Web site at www.icotherapeutics.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: